‌

US Patent 11311519 Treatment of hepatitis delta virus infection

Patent 11311519 was granted and assigned to Eiger BioPharmaceuticals on April, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Eiger BioPharmaceuticals

0

Current Assignee

Eiger BioPharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jeffrey S. Glenn0

David A. Cory0

Ingrid Choong0

Date of Patent

April 26, 2022

0

Patent Application Number

169961470

Date Filed

August 18, 2020

0

Patent Citations

US Patent 10076512 Treatment of hepatitis delta virus infection

0

US Patent 10828283 Treatment of hepatitis delta virus infection

Patent Primary Examiner

0

CPC Code

0

0

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11311519 Treatment of hepatitis delta virus infection

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.